Operative Risk After Pancreatic Surgery in Patients With End Stage Renal Disease

Background End-stage renal disease patients often present risk factors for many surgical complications. However, the severity of renal failure and whether the patient is receiving renal replacement therapy are also related to the difficulty of pancreatic and other major surgeries, causing many end-stage renal disease patients to hesitate when choosing surgery options. IV. Objectives To compare whether surgical methods, severity of renal failure, use of renal replacement therapy, and lesion margin clearance rates affect the patient's occurrence of surgical complications, length of hospital stay, length of ICU stay, re-operation or severe complications, medical costs, and related quality of life. V. Methodology and Procedures Data Collection The Principal Investigator and Co-Investigator will retrospectively review medical records to collect basic data of patients with end-stage renal disease who underwent pancreatic surgery at this hospital. This includes preoperative and postoperative blood tests (blood counts, biochemistry, tumor markers, glucose-related, lipid-related) and imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.). This data will be used to compare the impact of surgical methods, renal failure severity, renal replacement therapy status, and margin clearance on surgical complications, hospital stay, ICU stay, re-operations, severe complications, medical costs, and quality of life. The goal is to analyze the prognosis, care priorities, and management outcomes for ESRD patients undergoing pancreatic surgery. From the hospital portal system, approximately 500 medical records of patients with pancreatic diseases who underwent pancreatic surgery or invasive treatment performed by the Principal Investigator and Co-Investigator between January 2005 and July 2021 will be collected. This observational study will collect routine imaging and laboratory tests performed at the hospital to analyze treatment indications, surgical indicators, and prognosis. Inclusion Criteria: 1. Males or females aged 20 years or older. 2. Patients scheduled to undergo pancreatic surgery. Exclusion Criteria: 1. Patients under 20 years of age at this hospital. 2. Presence of other active malignancies prior to diagnosis. 3. Minors, pregnant women, breastfeeding women, and patients with psychiatric disorders. Treatment Flow For patients after pancreatic surgery, daily records will be kept regarding vital signs, drainage volume, intake/output balance, dietary intake and emptying, occurrence/management/severity of complications, length of hospital stay, length of ICU stay, re-operations or severe complications, medical costs, related quality of life, and nutritional status. Additionally, CT, MRI, endoscopy, and upper GI series examinations may be used to track and assist in analyzing the causes of postoperative complications. Statistical Analysis The study will analyze the surgical prognosis, care priorities, common complications, and the management and outcomes of the hospital team for ESRD patients undergoing pancreatic surgery, aiming to provide diverse and specific treatment recommendations in the future. Confidentiality and Privacy Protection To ensure patient privacy and personal information security, after querying the relevant data of enrolled subjects, the data sheet will use new codes to represent the subjects' identities. Experimenters and analysts will only have access to this de-linked data sheet for analysis. All electronic data will be password-protected and accessible only by specific personnel related to this project. All data not used or after analysis will be stored at the NTU Department of Surgery for 15 years and then destroyed by shredder or incineration to remove identifiable personal data, unless required for medical or research purposes. Researchers (including external personnel) will sign a written pledge stating that medical record data will not be reused, disclosed to third parties, or used for purposes outside this study, unless required by law or audited by the Research Ethics Committee. If researchers encounter data that cannot directly identify identity, they will not attempt to identify individual patients. Collaborating external academic institutions or manufacturers must sign a research collaboration agreement.